scholarly journals Long-Term Alteration of Intestinal Microbiota in Patients with Ulcerative Colitis by Antibiotic Combination Therapy

PLoS ONE ◽  
2014 ◽  
Vol 9 (1) ◽  
pp. e86702 ◽  
Author(s):  
Shigeo Koido ◽  
Toshifumi Ohkusa ◽  
Takayuki Kajiura ◽  
Junko Shinozaki ◽  
Manabu Suzuki ◽  
...  
2017 ◽  
Vol 112 (10) ◽  
pp. 1621-1623 ◽  
Author(s):  
Sarah Fischer ◽  
Timo Rath ◽  
Carol-Immanuel Geppert ◽  
Bernhard Manger ◽  
Georg Schett ◽  
...  

2015 ◽  
Vol 110 ◽  
pp. S813
Author(s):  
Hiroko Kobayashi ◽  
Shintaro Tsukinaga ◽  
Tomoya Kanai ◽  
Shinichiro Takami ◽  
Keisuke Saito ◽  
...  

2017 ◽  
Vol 23 (1) ◽  
pp. 116-125 ◽  
Author(s):  
Dai Ishikawa ◽  
Takashi Sasaki ◽  
Taro Osada ◽  
Kyoko Kuwahara-Arai ◽  
Keiichi Haga ◽  
...  

2003 ◽  
Vol 124 (4) ◽  
pp. A68 ◽  
Author(s):  
Toshifumi Ohkusa ◽  
Hiroto Miwa ◽  
Osamu Kobayashi ◽  
Tsuyoshi Terai ◽  
Tetsuya Nomura ◽  
...  

2021 ◽  
Vol 12 ◽  
pp. 204062232110287
Author(s):  
Yuriko Nishikawa ◽  
Nobuhiro Sato ◽  
Shintaro Tsukinaga ◽  
Kan Uchiyama ◽  
Shigeo Koido ◽  
...  

Aims: An antibiotic combination of amoxicillin, tetracycline and metronidazole (ATM) is effective for ulcerative colitis (UC), but this regimen is discontinued in some cases due to adverse events. This study aimed to assess a revised combination, namely, amoxicillin, fosfomycin and metronidazole (AFM), in UC patients with the goal of reducing side effects while maintaining therapeutic efficacy. Methods: A prospective open-label trial was undertaken in 104 adult UC patients. A combination of oral amoxicillin (1500 mg), fosfomycin (3000 mg) and metronidazole (750 mg) was administered to patients daily for 2–4 weeks in addition to their conventional medication. Clinical assessment was performed using the Lichtiger index before treatment and at 0, 3, 6, 9 and 12 months and 2 and 3 years. Endoscopic evaluation was performed using the Mayo score before treatment and at 3 and 12 months. Results: The compliance rate was 99.2%. Response and remission rates were 80.8% and 63.5% at completion, 73.1% and 64.4% at 3 months, and 39.4% for both at 12 months, respectively. Of the 41 patients who were in remission at 12 months, 63.4% maintained that status until the 2-year follow-up. Similarly, 69.2% of those in remission at 2 years remained relapse free at the 3-year follow-up. Side effects were observed in 44.2% of the participants. Fever occurred in one patient (1.0%), which was lower than the rate observed with ATM therapy. Conclusion: These results indicate that AFM therapy induces remission and is appropriate for long-term maintenance of UC while producing fewer and milder adverse events than ATM therapy. Clinical trials: This study was registered in the University Hospital Medical Information Network (No. R000046546).


2010 ◽  
Vol 76 (2) ◽  
pp. 118-119
Author(s):  
Hiroto Ishii ◽  
Shintaro Tsukinaga ◽  
Shunichi Odahara ◽  
Kan Uchiyama ◽  
Katsushi Amano ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document